Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

When is the expected fda decision date for apotex's ruxolitinib resubmission?
When does guselkumab patent expire?
Patent expiry trametinib?
Patent expiration eu dabrafenib?
Zemdri plazomicin nce gain exclusivity 2028 patent 2031?

Jardiance patent expiration generic launch?

See the DrugPatentWatch profile for Jardiance

What happens when the Jardiance patent expires?

The patent for Jardiance (empagliflozin), a type-I sodium-glucose cotransporter 2 (SGLT2) inhibitor developed by Boehringer Ingelheim (BI) and Eli Lilly, is set to expire in 2027 in the US [1]. This has significant implications for the future of the drug, its price, and availability of generic alternatives.

Who will manufacture Jardiance generics?

Several companies are already working on developing their own versions of Jardiance, including Mylan N.V. (now Viatris), Sandoz (Novartis), Hikma Pharmaceuticals, and Teva Pharmaceutical Industries Limited [2]. These companies will likely enter the US market with their generic versions of Jardiance after the patent expires.

Impact on Jardiance price and patients?

The entry of generic versions of Jardiance is expected to lead to significant price reductions [3]. This will potentially benefit patients by making the treatment more affordable. However, the exact price of generic Jardiance will depend on various factors, including market competition and the number of generic entrants.

Comparison with other SGLT2 inhibitors?

Jardiance will be competing with other SGLT2 inhibitors, such as Invokana (canagliflozin) and Farxiga (dapagliflozin), which have already lost their patents. This increased competition may further push prices down and encourage more SGLT2 inhibitor development.

Can biosimilars enter before patent expiry?

Currently, it's unclear whether biosimilars of Jardiance, a biological product developed using biotechnology, can enter the market before the patent expires [4]. The regulatory pathway for biosimilars in the US is still evolving, and there may be opportunities for biosimilar developers to enter the market before the patent expires.

Sources:

[1] DrugPatentWatch.com
[2] Statnews.com
[3] Bloomberg.com
[4] BioPharmaDive.com

Note: The exact date of the patent expiration, 2027, is based on available data and may be subject to change as patent timelines can be complex.



Other Questions About Jardiance :

when will jardiance be generic Jardiance pricing? Cost of jardiance with insurance? Jardiance with ckd? When do jardiance patent expire? Wann lauft der patentschutz fur jardiance aus? How expensive is jardiance?

AI-Drug Label Prescribing Information Alignment Report

Patient Risk: Low

Summary

The provided AI claims concern patent/generic/biosimilar regulatory timelines and competitive landscape, none of which are supported or verifiable from the supplied Jardiance prescribing information excerpts. Therefore, label alignment cannot be established for these claims.

Category Scores

Accurate Statements

Jardiance is an SGLT2 inhibitor.
Supported by Label Section 12.1 (Mechanism of Action): empagliflozin is an inhibitor of SGLT2.

Unsupported Statements

The patent for Jardiance (empagliflozin) is set to expire in 2027 in the US.
Not supported by the provided prescribing information excerpts.
Several companies are working on developing generic versions of Jardiance, including Mylan (now Viatris), Sandoz (Novartis), Hikma Pharmaceuticals, and Teva.
Not addressed in the provided prescribing information excerpts.
Generic versions of Jardiance are expected to enter the US market after the patent expires.
Not addressed in the provided prescribing information excerpts.
The entry of generic versions of Jardiance is expected to lead to significant price reductions.
Not addressed in the provided prescribing information excerpts.
Generic Jardiance pricing will depend on market competition and the number of generic entrants.
Not addressed in the provided prescribing information excerpts.
Jardiance will be competing with other SGLT2 inhibitors such as Invokana (canagliflozin) and Farxiga (dapagliflozin).
Not addressed in the provided prescribing information excerpts.
Invokana and Farxiga have already lost their patents.
Not addressed in the provided prescribing information excerpts.
The regulatory pathway for biosimilars in the US is still evolving.
Not addressed in the provided prescribing information excerpts.
It is currently unclear whether biosimilars of Jardiance can enter the market before the patent expires.
Not addressed in the provided prescribing information excerpts.

Contradictions

Important Omissions

Any labeling-supported dosing, contraindications, boxed warnings, warnings/precautions, administration, or monitoring information relevant to the claims made (patents/generics/biosimilars/competition).
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
The only label-supported factual claim concerns mechanism of action (SGLT2 inhibitor). The other claims are about patent/generic/biosimilar timelines and market/competition and are not safety claims grounded in the prescribing information excerpts provided.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk High

Recommendation

Not Aligned

Primary Issue
Most claims are not supported or verifiable from the supplied Jardiance FDA-approved prescribing information excerpts (which focus on indications, dosing, contraindications, and clinical safety).

Suggested Improvement
Limit claims to what is stated in the prescribing information excerpts (e.g., mechanism of action as an SGLT2 inhibitor) and avoid specific patent expiry, generic/biosimilar market-entry timing, or competitor patent status unless provided in the label.

Drug Brand Mention Assessment

Branding Score
62
Visibility
57
Mentioned
Ranking
#1
Sentiment
70
Recommendation Status
mentioned only
Brand Perception
Best Known For

empagliflozin (a type-I sodium-glucose cotransporter 2 (SGLT2) inhibitor)

Core Claims
  • The patent for Jardiance (empagliflozin) is set to expire in 2027 in the US.
  • Several companies are already working on developing their own versions of Jardiance.
  • The entry of generic versions of Jardiance is expected to lead to significant price reductions.
  • Jardiance will be competing with other SGLT2 inhibitors, such as Invokana and Farxiga.
  • It is unclear whether biosimilars of Jardiance can enter the market before the patent expires.
Differentiators
  • Patent expiration timing (2027 in the US) is positioned as a key driver for generics and pricing.
  • Its generic entry is expected to increase price competition for the drug class.
  • Uncertainty is flagged for biosimilars entering before patent expiry.
Pricing Perception: Mid Range
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
Janssen Pharmaceuticals 30%
50 #2 No
AstraZeneca 28%
50 #3 No